Wilson R S, Connellan S J
Thorax. 1980 Nov;35(11):873-6. doi: 10.1136/thx.35.11.873.
Nine patients with severe chronic airway obstruction secondary to chronic bronchitis and emphysema all preferred nebulised salbutamol solution to placebo in a double-blind controlled trial. Four of the patients who had previously received domiciliary nebulised salbutamol failed to complete the placebo period, though all completed the active period. Five others improved subjectively on active therapy, and showed a significant improvement in morning and evening peak flows. Symptom scores for breathlessness, wheezing, and sputum production were lower in the active treatment period and standard aerosol usage fell, although these changes might have been due to chance. Patients with severe chronic airway obstruction who do not respond to conventional bronchodilator therapy should be considered for this form of treatment.
在一项双盲对照试验中，9例继发于慢性支气管炎和肺气肿的严重慢性气道阻塞患者均更倾向于雾化沙丁胺醇溶液而非安慰剂。4例先前接受过家庭雾化沙丁胺醇治疗的患者未能完成安慰剂阶段，但均完成了活性药物阶段。另外5例患者在活性治疗中主观症状改善，且早晚峰值呼气流速有显著提高。活性治疗期呼吸急促、喘息和咳痰的症状评分较低，标准气雾剂使用量下降，尽管这些变化可能是偶然所致。对于对传统支气管扩张剂治疗无反应的严重慢性气道阻塞患者，应考虑这种治疗方式。
